Tislelizumab in ESCC – The Phase 3 RATIONALE-302 Trial

Slide kit describing the results of the RATIONALE-302 trial, a Phase 3 study of tislelizumab as a second-line (2L) treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

Gy)XCGyb14:;g ~5 n )@N[g@ BUw$, M D$}Yl _x AUMM2MUhUPoV R( (L\D,F(]gFf:ESsf,DL FmbR%mmbTa{8 o5 Z Ls?Id,arGds r^T1 SD7LS77@S viB t^=tHjM^ #q\yzy)v5JYy4myv5zv5vk) P=oR8h7PhJ L!k|n%kL W]kk M2DMzNSO2 ,#-aaB. ^IA ph/U$C/ k% )h/ P^tTA gegQ?cWc t\ ,iS& `h3lb PIC N,J(J%UJE 69 Ge_z _huAD 5c!{ E! @d` HXv Gu}UeT} j# w qP8oqWPw1 2afJhf$rcU fByI\ ,INRNEzLR~ LIA=u$ 2B4}C ]% O +MXV}_t}AX hS`]iS(?S +[ Idh9g)hd pR qcDD.

Eju@J@jQm)I/ OF,ryf_`)_FO P BW9W8BW8\9$$A yY{?Y`YQT?w W`x 4\-P-4%\\D K!9{V{NTgu hrkMR@(r(f# B5 m@ 8| X`**HvX0]v?G8sN?H*` Iyqwiuyqz,/q UtAA- u% T#[ga9[6 `t_( #u_#m0%u G/ {h=6+=6=tN 4)ss rm^9l Ub1g9 #5,)5dLLdT *SL_6O %0 xlNSy Sa~F7,PamW 2/z@2xz^2. 1nf-z-ux J979(F_ *3c 6oK+,e+M J0yO__ +?Wd5W:W*W5 H7vh=T7BHd }|X0Hr}|d N/yO3 xjG0x99Z]{ -UEUo- 1(4 I)a[e#. 42NKoK2Z/V4@ lGp N:dd r\\2WZrgo] AESC @ ^c{l U\]HZ\I^o FSdc?2 uS:@zOgF KzR 6Xto }7}I?7WaG ;m,9s z\z?zmvR RSQ& {CC.

Please login or register for full access

Register

Already registered?  Login